Table 1.

Relationship between the expression of the long intergenic non-protein coding RNA 665 (LINC00665) gene and clinical parameters in The Cancer Genome Atlas (TCGA).

Clinicopathological feature		n	LINC00665 expression in TCGA database
			M ±SD	t	P
Tissue	Adjacent	50	5.7526±0.9214	−8.550a	<0.0001
	HCC	370	7.2643±2.2990
Gender	Male	255	6.7842±2.5317	−4.178	<0.0001
	Female	122	7.8508±2.2100
Neoplasm histology grade 1	I	55	6.8179±1.7326	F=4.045b	0.008
	II	177	7.0568±2.2893
	III	122	7.6324±2.4559
	IV	12	8.7823±2.2915
Neoplasm histology grade 2	I–II	232	7.0001±2.1691	−2.878	0.004
	III–IV	134	7.7354±2.4556
Pathologic stage I	I	170	7.0134±2.2042	F=2.318	0.075
	II	86	7.2462±2.4777
	III	82	7.7017±2.3357
	IV	5	8.7059±1.5359
Pathologic stage II	I–II	156	7.0916±2.2975	−2.341	0.020
	III–IV	87	7.7594±2.3029
Pathologic tumor I	TI	180	7.0226±2.1824	F=1.845	0.139
	TII	93	7.3853±2.4490
	TIII	80	7.7032±2.3744
	TIV	13	6.9036±1.9319
Pathologic tumor II	I–II	273	7.1462±2.2787	−1.619	0.106
	III–IV	93	7.5914±2.3250
Pathologic lymph node	−	252	7.3046±2.3385	−2.900	0.057
	+	4	9.5284±1.5048
Metastasis	−	266	7.4298±2.3195	−1.857	0.155
	+	4	8.9711±1.6359
Person neoplasm cancer status	−	202	7.3287±2.1887	0.510	0.611
	+	150	7.2021±2.3876
Radiation therapy	−	338	7.2844±2.2843	1.312	0.190
	+	9	6.2725±2.2347
Relative family cancer history	−	207	7.3254±2.3148	0.167	0.867
	+	112	7.2810±2.1503
Vascular invasion I	None	205	6.9705±2.2014	F=4.728	0.009
	Micro	93	7.4040±2.4094
	Macro	17	8.6168±2.3080
Vascular invasion II	−	205	6.9705±2.2014	−2.237	0.026
	+	110	7.5914±2.4240

^aStudent’s two-sample independent t-test was performed;

^bOne-way analysis of variance (ANOVA) test was performed.